
Releases
Capricor Therapeutics Faces Class Action Over Deramiocel Disclosures
Investors who purchased Capricor Therapeutics securities between December 17, 2025, and July 26, 2026, are now the target of a class action lawsuit filed by Bronstein, Gewirtz & Grossman, LLC. The litigation claims the company misled shareholders regarding the regulatory pathway for its Duchenne muscular dystrophy treatment, Deramiocel.
























